Bone Biologics Corp Stock Total Debt
| BBLG Stock | USD 0.82 0.03 3.53% |
Bone Biologics Corp fundamentals help investors to digest information that contributes to Bone Biologics' financial success or failures. It also enables traders to predict the movement of Bone Stock. The fundamental analysis module provides a way to measure Bone Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bone Biologics stock.
The current Total Debt To Capitalization is estimated to decrease to -5.62. Bone | Total Debt |
Bone Biologics Corp Company Total Debt Analysis
Bone Biologics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Bone Biologics Total Debt | 377.71 K |
Most of Bone Biologics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bone Biologics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bone Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Bone Biologics is extremely important. It helps to project a fair market value of Bone Stock properly, considering its historical fundamentals such as Total Debt. Since Bone Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bone Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bone Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
Bone Total Debt Historical Pattern
Today, most investors in Bone Biologics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bone Biologics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bone Biologics total debt as a starting point in their analysis.
Bone Biologics Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Bone Net Debt
Net Debt |
|
Based on the latest financial disclosure, Bone Biologics Corp has a Total Debt of 377.71 K. This is 99.99% lower than that of the Health Care Equipment & Supplies sector and 99.98% lower than that of the Health Care industry. The total debt for all United States stocks is 99.99% higher than that of the company.
Bone Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bone Biologics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bone Biologics could also be used in its relative valuation, which is a method of valuing Bone Biologics by comparing valuation metrics of similar companies.Bone Biologics is currently under evaluation in total debt category among its peers.
Bone Biologics Institutional Holders
Institutional Holdings refers to the ownership stake in Bone Biologics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bone Biologics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bone Biologics' value.| Shares | Ubs Group Ag | 2024-12-31 | 21.9 K | Geode Capital Management, Llc | 2024-12-31 | 15.4 K | Hrt Financial Llc | 2024-12-31 | 14.7 K | Citigroup Inc | 2024-12-31 | 4.9 K | Tower Research Capital Llc | 2024-12-31 | 3.4 K | Bank Of America Corp | 2024-12-31 | 20.0 | Sbi Securities Co Ltd | 2024-12-31 | 1.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 0.0 | Cwm, Llc Duplicate | 2024-12-31 | 0.0 | Mcmahon Financial Advisors, Llc | 2024-12-31 | 0.0 |
Bone Fundamentals
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.69 | ||||
| Current Valuation | (549.65 K) | ||||
| Shares Outstanding | 3.27 M | ||||
| Shares Owned By Insiders | 2.12 % | ||||
| Shares Owned By Institutions | 2.14 % | ||||
| Number Of Shares Shorted | 130.43 K | ||||
| Price To Earning | (15.45) X | ||||
| Price To Book | 0.80 X | ||||
| EBITDA | (4.22 M) | ||||
| Net Income | (4.11 M) | ||||
| Cash And Equivalents | 5.45 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 377.71 K | ||||
| Current Ratio | 80.11 X | ||||
| Book Value Per Share | 1.18 X | ||||
| Cash Flow From Operations | (4.12 M) | ||||
| Short Ratio | 0.66 X | ||||
| Earnings Per Share | (4.83) X | ||||
| Target Price | 16.5 | ||||
| Beta | 0.93 | ||||
| Market Capitalization | 2.78 M | ||||
| Total Asset | 3.86 M | ||||
| Retained Earnings | (85.02 M) | ||||
| Working Capital | 3.48 M | ||||
| Current Asset | 1.07 M | ||||
| Current Liabilities | 2.16 M | ||||
| Net Asset | 3.86 M |
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Bone Biologics Piotroski F Score and Bone Biologics Altman Z Score analysis. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.